It should, however, be noted that the therapeutic potential of p38 inhibitors was thoroughly evaluated in clinical trials in many inflammatory diseases, in particular rheumatoid arthritis, showing limited efficacy and unacceptable safety profiles (45). The gene discussed is MAPK14; the disease is rheumatoid arthritis.